 NEW YORK--BUSINESS WIRE--WaterMill Asset Management Corp. together with its affiliates, WaterMill or we, which collectively with the other participants in its consent solicitation beneficially owns approximately 3.3 of the outstanding shares of Ziopharm Oncology, Inc. NASDAQ: ZIOP Ziopharm or the Company, today issued the below letter to shareholders. As a reminder, WaterMill is encouraging shareholders to consent to all of its proposals by voting on the WHITE consent card. We 